clinmedКлиническая медицинаClinical Medicine (Russian Journal)0023-21492412-1339ООО «Медицинское информационное агентство»10.30629/0023-2149-2025-103-5-361-368clinmed-1143Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL INVESTIGATIONSОценка прогностической способности отношения тромбоцитов к лимфоцитам у пациентов с реваскулиризацией миокарда после коронавирусной инфекцииAssessment of the prognostic ability of the platelet-to-lymphocyte ratio in patients with myocardial revascularization after coronavirus infectionhttps://orcid.org/0000-0003-3198-1860БатеноваГ. Б.BatenovaG. B.

Батенова Гульнара Баяхметовна – ассистент кафедры неотложной медицины; кардиолог

Семей;

Москва

Gulnara B. Batenova – assistant of the Department of Emergency; cardiologist

Semey;

Moscow

gulnara_batenova@mail.ruhttps://orcid.org/0000-0002-9118-3708ДедовЕ. И.DedovE. I.

Дедов Евгений Иванович – д-р мед. наук, профессор кафедры госпитальной терапии им. академика Г.И. Сторожакова, ревматолог

Москва

Evgeniy I. Dedov – Doctor of Medical Sciences, Professor of the Department of Hospital Therapy named after Academician G.I. Storozhakova, rheumatologist

Moscow

https://orcid.org/0000-0001-7201-1399ОреховА. Ю.OrekhovA. Yu.

Орехов Андрей Юрьевич – ассистент кафедры терапии; кардиолог

Семей

Andrey Yu. Orekhov – Assistant of the Department of Therapy; cardiologist

Semey

https://orcid.org/0000-0001-8391-8842ЫгиеваД. Г.YgievaD. G.

Ыгиева Диана Габдыгалиевна – ассистент кафедры неотложной медицины; терапевт

Семей

Diana G. Ygiyeva – Assistant of the Department of Emergency Medicine; therapist

Semey

https://orcid.org/0000-0001-7206-8029ПивинМ. Р.PivinaM. R.

Пивин Максим Русланович – резидент

Семей

Maxim R. Pivin – resident

Semey

https://orcid.org/0000-0002-8035-4866ПивинаЛ. М.PivinaL. M.

Пивина Людмила Михайловна – канд. мед. наук, профессор кафедры неотложной медицины; врач-терапевт

Семей

Lyudmila M. Pivina – Candidate of Medical Sciences, Professor of the Department of Emergency Medicine; internist 

Semey

НАО «Медицинский университет Семей»; ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава РоссииКазахстанSemey Medical University; N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of the RussiaKazakhstanФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава РоссииРоссияN.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of the RussiaRussian FederationНАО «Медицинский университет Семей»КазахстанSemey Medical UniversityKazakhstan«Центр ядерной медицины и онкологии» управления здравоохранения области АбайКазахстанCenter for Nuclear Medicine and Oncology of the Abai Regional Health DepartmentKazakhstan2025220920251035361368Copyright © Батенова Г.Б., Дедов Е.И., Орехов А.Ю., Ыгиева Д.Г., Пивин М.Р., Пивина Л.М., 20252025Батенова Г.Б., Дедов Е.И., Орехов А.Ю., Ыгиева Д.Г., Пивин М.Р., Пивина Л.М.Batenova G.B., Dedov E.I., Orekhov A.Y., Ygieva D.G., Pivina M.R., Pivina L.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinmedjournal.com/jour/article/view/1143

Несмотря на достижения интервенционной кардиологии, рестеноз коронарных сосудов остается актуальной проблемой. Важным фактором в патогенезе рестеноза является процесс воспаления в сосудистой интиме.

Цель настоящего исследования – оценить взаимосвязь между отношением тромбоцитов к лимфоцитам (ОТЛ) и клиническими илабораторными показателями у пациентов с повторной реваскуляризацией миокарда, а также проанализировать его прогностическую ценность для клинических исходов заболевания.

Материал и методы

Материал и методы. Поперечное исследование включало 931 пациента, которым была проведена повторная реваскуляризация миокарда в период с мая 2020 по май 2023 г. У 420 пациентов основной группы был выявлен рестеноз стента, из них у 162 пациентов ранее был COVID-19. Контрольная группа включала 511 пациентов без рестеноза стента (107 пациентов ранее перенесли COVID-19). Все зарегистрированные события были проверены по электронным записям больницы из Комплексной медицинской информационной системы.

Результаты

Результаты. Регрессионный анализ показал статистически значимую связь ОТЛ с уровнем нейтрофилов и креатинина в обеих группах исследования, а также с АСТ в основной группе исследования. Показатель ОТЛ не явился значимым предиктором для инфаркта миокарда с рестенозом коронарных артерий (ОШ = 1,0). Также не было найдено зависимости между выживаемостью больных с повторной реваскуляризацией от ОТЛ.

Вывод

Вывод. Найдена связь ОТЛ с некоторыми лабораторными показателями, однако его прогностическая ценность в отношении инфаркта миокарда с рестенозом коронарных артерий не установлена.

Despite the advances in interventional cardiology, the problem of coronary restenosis remains relevant. An important factor in the pathogenesis of restenosis is the inflammatory process in the vascular intima. The aim of the study is to evaluate the relationship between the platelet-to-lymphocyte ratio (PLR), clinical and laboratory parameters in patients with repeat myocardial revascularization, and to analyze its prognostic value for clinical outcomes.

Material and methods

Material and methods. A crosssectional study included 931 patients who underwent repeat myocardial revascularization between May 2020 and May 2023. In-stent restenosis was detected in 420 patients in the main group, of which 162 patients previously had COVID-19. The control group included 511 patients without in-stent restenosis (107 patients previously had COVID-19). All registered events were verified by the hospital's electronic records in the Integrated Medical Information System.

Results

Results. The regression analysis showed a statistically significant association of PLR with neutrophil and creatinine levels in both study groups, as well as with AST in the main group. PLR is not a significant predictor of myocardial infarction with coronary artery restenosis (OR = 1.0). Also, no relationship was found between the survival of patients with repeat revascularization and PLR.

Conclusion

Conclusion. An association of PLR with some laboratory parameters was determined, but its prognostic value for myocardial infarction with coronary artery restenosis was not found.

ишемическая болезнь сердцарестеноз коронарных артерийчрескожное коронарное вмешательствоотношение тромбоцитов к лимфоцитамCOVID-19coronary artery diseasecoronary artery restenosispercutaneous coronary interventionplatelet-to-lymphocyte ratioCOVID-19Исследование выполнено при финансовой поддержке Комитета науки Министерства образования и науки Республики Казахстан (грант №AP19677465 «Совершенствование системы оказания медицинской помощи лицам с предшествующей реваскуляризацией миокарда, перенесшим коронавирусную инфекцию»).The study was carried out with the financial support of the Committee of Science of the Ministry of Education and Science of the Republic of Kazakhstan (grant № AP19677465 «Improvement of the system of medical care for people with previous myocardial revascularization who suffered from coronavirus infection».ReferencesKim M.S., Dean L.S. In-stent restenosis. Cardiovasc. Ther. 2011;29(3):190–198. DOI: 10.1111/j.1755-5922.2010.00155.xKim M.S., Dean L.S. In-stent restenosis. Cardiovasc. Ther. 2011;29(3):190–198. DOI: 10.1111/j.1755-5922.2010.00155.xLiang S., Aiqun M., Jiwu L., Ping Z. TLR3 and TLR4 as potential clinical biomarkers for in-stent restenosis in drug-eluting stents patients. Immunol. Res. 2016;64(2):424–30. DOI: 10.1007/s12026-015-8685-6Liang S., Aiqun M., Jiwu L., Ping Z. TLR3 and TLR4 as potential clinical biomarkers for in-stent restenosis in drug-eluting stents patients. Immunol. Res. 2016;64(2):424–30. DOI: 10.1007/s12026-015-8685-6Yılmaz S., Sen F., Ünal S., Yayla C., Özeke Ö., Aras D., Topaloglu S., Aydogdu S. Usefulness of the platelet-to-lymphocyte ratio in predicting bare-metal stent restenosis. Scand. Cardiovasc. J. 2015; 49(1):39–44. DOI: 10.3109/14017431.2014.989537Yılmaz S., Sen F., Ünal S., Yayla C., Özeke Ö., Aras D., Topaloglu S., Aydogdu S. Usefulness of the platelet-to-lymphocyte ratio in predicting bare-metal stent restenosis. Scand. Cardiovasc. J. 2015; 49(1):39–44. DOI: 10.3109/14017431.2014.989537Niccoli G., Dato I., Imaeva A.E., Antonazzo Panico R., Roberto M., Burzotta F., Aurigemma C., Trani C., Gramegna M., Leone A.M., Porto I., Crea F. Association between inflammatory biomarkers and in-stent restenosis tissue features: an Optical Coherence Tomography Study. Eur. Heart J. Cardiovasc. Imaging. 2014;15(8):917–25. DOI: 10.1093/ehjci/jeu035Niccoli G., Dato I., Imaeva A.E., Antonazzo Panico R., Roberto M., Burzotta F., Aurigemma C., Trani C., Gramegna M., Leone A.M., Porto I., Crea F. Association between inflammatory biomarkers and in-stent restenosis tissue features: an Optical Coherence Tomography Study. Eur. Heart J. Cardiovasc. Imaging. 2014;15(8):917–25. DOI: 10.1093/ehjci/jeu035Wang Z., Liu C., Fang H. Blood cell parameters and predicting coronary in-stent restenosis. Angiology. 2019;70(8):711–718. DOI: 10.1177/0003319719830495Wang Z., Liu C., Fang H. Blood cell parameters and predicting coronary in-stent restenosis. Angiology. 2019;70(8):711–718. DOI: 10.1177/0003319719830495Zaher N., Sattar Y., Mahmood S., Vacek T., Alraies M.C. COVID-19 infection complicated by a complete occlusion of the left circumflex artery with acute restenosis after drug-eluting stent placement. Cureus. 2020;12(9):e10708. DOI: 10.7759/cureus.10708Zaher N., Sattar Y., Mahmood S., Vacek T., Alraies M.C. COVID-19 infection complicated by a complete occlusion of the left circumflex artery with acute restenosis after drug-eluting stent placement. Cureus. 2020;12(9):e10708. DOI: 10.7759/cureus.10708Dotsenko O., Chaturvedi N., Thom S.A., Wright A.R., Mayet J., Shore A., Schalkwijk C., Hughes A.D. Platelet and leukocyte activation, atherosclerosis and inflammation in European and South Asian men. J. Thromb. Haemost. 2007;5(10):2036–2042. DOI: 10.1111/j.1538-7836.2007.02711.xDotsenko O., Chaturvedi N., Thom S.A., Wright A.R., Mayet J., Shore A., Schalkwijk C., Hughes A.D. Platelet and leukocyte activation, atherosclerosis and inflammation in European and South Asian men. J. Thromb. Haemost. 2007;5(10):2036–2042. DOI: 10.1111/j.1538-7836.2007.02711.xSarkar S., Kannan S., Khanna P., Singh A.K. Role of plateletto-lymphocyte count ratio (PLR), as a prognostic indicator in COVID-19: A systematic review and meta-analysis. J. Med. Virol. 2022;94(1):211–221. DOI: 10.1002/jmv.27297Sarkar S., Kannan S., Khanna P., Singh A.K. Role of plateletto-lymphocyte count ratio (PLR), as a prognostic indicator in COVID-19: A systematic review and meta-analysis. J. Med. Virol. 2022;94(1):211–221. DOI: 10.1002/jmv.27297Falk E., Nakano M., Bentzon J.F., Finn A.V., Virmani R. Update on acute coronary syndromes: the pathologists' view. Eur. Heart J. 2013;34(10):719–28. DOI: 10.1093/eurheartj/ehs411Falk E., Nakano M., Bentzon J.F., Finn A.V., Virmani R. Update on acute coronary syndromes: the pathologists' view. Eur. Heart J. 2013;34(10):719–28. DOI: 10.1093/eurheartj/ehs411Lindemann S., Krämer B., Seizer P., Gawaz M. Platelets, inflammation and atherosclerosis. J. Thromb. Haemost. 2007; 5 Suppl 1:203–211. DOI: 10.1111/j.1538-7836.2007.02517.xLindemann S., Krämer B., Seizer P., Gawaz M. Platelets, inflammation and atherosclerosis. J. Thromb. Haemost. 2007; 5 Suppl 1:203–211. DOI: 10.1111/j.1538-7836.2007.02517.xHorne B.D., Anderson J.L., John J.M., Weaver A., Bair T.L., Jensen K.R., Renlund D.G, Muhlestein J.B. Intermountain Heart Collaborative Study Group. Which white blood cell subtypes predict increased cardiovascular risk? J. Am. Coll. Cardiol. 2005;45(10):1638–1643. DOI: 10.1016/j.jacc.2005.02.054Horne B.D., Anderson J.L., John J.M., Weaver A., Bair T.L., Jensen K.R., Renlund D.G, Muhlestein J.B. Intermountain Heart Collaborative Study Group. Which white blood cell subtypes predict increased cardiovascular risk? J. Am. Coll. Cardiol. 2005;45(10):1638–1643. DOI: 10.1016/j.jacc.2005.02.054Frangogiannis N.G., Smith C.W., Entman M.L. The inflammatory response in myocardial infarction. Cardiovasc Res. 2002;53:31–47. DOI: 10.1016/S0008-6363(01)00434-5Frangogiannis N.G., Smith C.W., Entman M.L. The inflammatory response in myocardial infarction. Cardiovasc Res. 2002;53:31–47. DOI: 10.1016/S0008-6363(01)00434-5Major A.S., Fazio S., Linton M.F. B-lymphocyte deficiency increases atherosclerosis in LDL receptor-null mice. Arterioscler. Thromb. Vasc. Biol. 2002;22:1892–1898. DOI: 10.1161/01.atv.0000039169.47943.eeMajor A.S., Fazio S., Linton M.F. B-lymphocyte deficiency increases atherosclerosis in LDL receptor-null mice. Arterioscler. Thromb. Vasc. Biol. 2002;22:1892–1898. DOI: 10.1161/01.atv.0000039169.47943.eeWidmer A., Linka A.Z., Attenhofer Jost C.H., Buergi B., Brunner-La Rocca H.P., Salomon F., Seifert B., Jenni R. Mechanical complications after myocardial infarction reliably predicted using C-reactive protein levels and lymphocytopenia. Cardiology. 2003;99(1):25–31. DOI: 10.1159/000068448Widmer A., Linka A.Z., Attenhofer Jost C.H., Buergi B., Brunner-La Rocca H.P., Salomon F., Seifert B., Jenni R. Mechanical complications after myocardial infarction reliably predicted using C-reactive protein levels and lymphocytopenia. Cardiology. 2003;99(1):25–31. DOI: 10.1159/000068448Li X.T., Fang H., Li D., Xu FQ., Yang B., Zhang R., An Y. Association of platelet to lymphocyte ratio with in-hospital major adverse cardiovascular events and the severity of coronary artery disease assessed by the Gensini score in patients with acute myocardial infarction. Chin. Med. J. 2020;133:415–423. DOI: 10.1097/CM9.0000000000000650Li X.T., Fang H., Li D., Xu FQ., Yang B., Zhang R., An Y. Association of platelet to lymphocyte ratio with in-hospital major adverse cardiovascular events and the severity of coronary artery disease assessed by the Gensini score in patients with acute myocardial infarction. Chin. Med. J. 2020;133:415–423. DOI: 10.1097/CM9.0000000000000650Azab B., Shah N., Akerman M., McGinn J.T.Jr. Value of platelet/ lymphocyte ratio as a predictor of all-cause mortality after non-STelevation myocardial infarction. J. Thromb. Thrombolysis. 2012;34:326–334. DOI: 10.1007/s11239-012-0718-6Azab B., Shah N., Akerman M., McGinn J.T.Jr. Value of platelet/ lymphocyte ratio as a predictor of all-cause mortality after non-STelevation myocardial infarction. J. Thromb. Thrombolysis. 2012;34:326–334. DOI: 10.1007/s11239-012-0718-6Sun X.P., Li J., Zhu W.W., Li D.B., Chen H., Li H.W., Chen W.M., Hua Q. Impact of platelet-to-lymphocyte ratio on clinical outcomes in patients with ST-segment elevation myocardial infarction. Angiology. 2017;68(4):346–353. DOI: 10.1177/0003319716657258Sun X.P., Li J., Zhu W.W., Li D.B., Chen H., Li H.W., Chen W.M., Hua Q. Impact of platelet-to-lymphocyte ratio on clinical outcomes in patients with ST-segment elevation myocardial infarction. Angiology. 2017;68(4):346–353. DOI: 10.1177/0003319716657258Maimaiti A., Li Y., Wang Y.T., Yang X., Li X.M., Yang Y.N., Ma Y.T. Association of platelet-to-lymphocyte count ratio with myocardial reperfusion and major adverse events in patients with acute myocardial infarction: a two-centre retrospective cohort study. BMJ Open. 2019;9(9):e025628. DOI: 10.1136/bmjopen-2018-025628Maimaiti A., Li Y., Wang Y.T., Yang X., Li X.M., Yang Y.N., Ma Y.T. Association of platelet-to-lymphocyte count ratio with myocardial reperfusion and major adverse events in patients with acute myocardial infarction: a two-centre retrospective cohort study. BMJ Open. 2019;9(9):e025628. DOI: 10.1136/bmjopen-2018-025628Lee Y.S.G., Baradi A., Peverelle M., Sultani R., Adams H., Garlick J., Wilson A.M. Usefulness of platelet-to-lymphocyte ratio to predict long-term all-cause mortality in patients at high risk of coronary artery disease who underwent coronary angiography. Am. J. Cardiol. 2018;121(9):1021–1026. DOI: 10.1016/j.amjcard.2018.01.018Lee Y.S.G., Baradi A., Peverelle M., Sultani R., Adams H., Garlick J., Wilson A.M. Usefulness of platelet-to-lymphocyte ratio to predict long-term all-cause mortality in patients at high risk of coronary artery disease who underwent coronary angiography. Am. J. Cardiol. 2018;121(9):1021–1026. DOI: 10.1016/j.amjcard.2018.01.018Li H., Zhou Y., Ma Y., Han S., Zhou L. The prognostic value of the platelet-to-lymphocyte ratio in acute coronary syndrome: a systematic review and meta-analysis. Kardiol. Pol. 2017;75:666–673. DOI: 10.5603/KP.a2017.0068Li H., Zhou Y., Ma Y., Han S., Zhou L. The prognostic value of the platelet-to-lymphocyte ratio in acute coronary syndrome: a systematic review and meta-analysis. Kardiol. Pol. 2017;75:666–673. DOI: 10.5603/KP.a2017.0068Li W., Liu Q., Tang Y. Platelet to lymphocyte ratio in the prediction of adverse outcomes after acute coronary syndrome: a meta-analysis. Sci. Rep. 2017;7:40426. DOI: 10.1038/srep40426.Li W., Liu Q., Tang Y. Platelet to lymphocyte ratio in the prediction of adverse outcomes after acute coronary syndrome: a meta-analysis. Sci. Rep. 2017;7:40426. DOI: 10.1038/srep40426.Wang H., Li L., Ma Y. Platelet‐to‐lymphocyte ratio a potential prognosticator in acute myocardial infarction: a prospective longitudinal study. Clin. Cardiol. 2023;46:632‐638. DOI: 10.1002/clc.24002Wang H., Li L., Ma Y. Platelet‐to‐lymphocyte ratio a potential prognosticator in acute myocardial infarction: a prospective longitudinal study. Clin. Cardiol. 2023;46:632‐638. DOI: 10.1002/clc.24002Alahwal H.M., Alsharif M.H., Alsharif M.H., Almohammadi AT., Al-Marzouki AF., Barefah AS., Bahashwan SM., Radhwi OO., Damanhouri GA. COVID-19-induced immune thrombocytopenia management approach: A case report and literature review. Clin. Case Rep. 2024;12(6):e9070. DOI: 10.1002/ccr3.9070Alahwal H.M., Alsharif M.H., Alsharif M.H., Almohammadi AT., Al-Marzouki AF., Barefah AS., Bahashwan SM., Radhwi OO., Damanhouri GA. COVID-19-induced immune thrombocytopenia management approach: A case report and literature review. Clin. Case Rep. 2024;12(6):e9070. DOI: 10.1002/ccr3.9070Chen Y., Liu J., Shao S., Song Z., Ma Y., Tuo Y., Fang L., Xu Y., Xu B., Gu W., Cao X., Chen J., Yang Y., Wang P., Zhang J., Xu Y., Yu D., Hou P., Meng K., Li Z., Liu G., Qu X., Ji L., Yang R., Zhang L. Characteristics and outcomes of COVID-19 in Chinese immune thrombocytopenia patients: A prospective cohort study. Br. J. Haematol. 2024;204(4):1207–1218. DOI: 10.1111/bjh.19198.Chen Y., Liu J., Shao S., Song Z., Ma Y., Tuo Y., Fang L., Xu Y., Xu B., Gu W., Cao X., Chen J., Yang Y., Wang P., Zhang J., Xu Y., Yu D., Hou P., Meng K., Li Z., Liu G., Qu X., Ji L., Yang R., Zhang L. Characteristics and outcomes of COVID-19 in Chinese immune thrombocytopenia patients: A prospective cohort study. Br. J. Haematol. 2024;204(4):1207–1218. DOI: 10.1111/bjh.19198.Tane M., Kosako H., Sonoki T., Hosoi H. TAFRO Syndrome and COVID-19. Biomedicines. 2024;12(6):1287. DOI: 10.3390/biomedicines12061287Tane M., Kosako H., Sonoki T., Hosoi H. TAFRO Syndrome and COVID-19. Biomedicines. 2024;12(6):1287. DOI: 10.3390/biomedicines12061287Шамес Д.В. Факторы риска рестенозов коронарных артерий при экстренном или плановом стентировании. Вестник современной клинической медицины. 2019;12(4):116–123.Shamis D.V. Risk factors for coronary artery restenosis during emergency or elective stenting. Bulletin of Modern Clinical Medicine. 2019;12(4):116–123. (In Russian). DOI: 10.20969/VSKM.2019.12(4).116-123

The authors declare that there are no conflicts of interest present.